OpenEvidence Launches Voice Mode and Closes $250M Series D at $12 Billion Valuation

OpenEvidence, the AI-powered medical search engine used by more than 860,000 licensed and verified U.S. clinicians, has launched Voice Mode — a hands-free feature that allows physicians, nurses, and pharmacists to ask clinical questions and receive spoken, evidence-based answers without touching a screen. The launch arrives alongside the company's disclosure of a $250 million Series D funding round at a $12 billion valuation.^[1]

Voice Mode is live across web and mobile and is free for all users. A clinician can tap an icon, ask a question, and hear a concise answer drawn from sources including the New England Journal of Medicine, JAMA, Cochrane Reviews, and NCCN guidelines. Every spoken response includes a written transcript and underlying references within the same conversation. A second tap mutes the microphone in noisy clinical settings, and clinicians can interrupt mid-answer to redirect the query.^[1]

"When I'm in the ED, I'm never at a workstation when I actually need an answer," said Ania Bilski, M.D., vice president of clinical AI at OpenEvidence and a practicing emergency medicine physician at UCSF and Kaiser Permanente.^[1]

Enterprise Expansion

The Voice Mode launch arrived alongside a new wave of health system partnerships. Cedars-Sinai joined Mount Sinai and Sutter Health in deploying OpenEvidence across their enterprises, giving physicians, nurses, pharmacists, and therapists access to the platform integrated directly into their electronic health record workflows. All three health systems skipped pilot programs and moved directly to enterprise-wide rollouts.^[1]

The platform now fields more than one million clinical questions per day and is actively used daily by the majority of U.S. physicians, spanning more than 10,000 hospitals and medical centers nationwide. A non-ad-supported enterprise pricing tier is in development for large systems that want customization beyond the core free product.^[1]

Funding and Investors

The $250 million Series D round was led by investors including Google Ventures, Nvidia, Thrive Capital, and Mayo Clinic. The round values the company at $12 billion, placing it among the most highly valued private companies in the health AI sector.^[2] Daniel Nadler, founder and CEO of OpenEvidence, said the company has spent years on the intelligence behind the platform and that Voice Mode advances the interface to match the everyday reality of practicing medicine.

The Broader Context

The clinical AI market is crowded with voice-based documentation tools. Microsoft introduced Dragon Copilot in March 2025, combining voice dictation and ambient listening to convert doctor-patient conversations into clinical notes. OpenEvidence's approach differs in that it targets the clinical decision-support layer — answering questions — rather than documentation. A PYMNTS Intelligence survey found that 60% of healthcare firms use AI for customer service and patient-facing interactions, the sector's single highest-reported use case, while integration with existing systems and fragmented data remain the two biggest barriers, each cited by 30% of healthcare executives.^[1]

References

1. PYMNTS. "OpenEvidence Brings Hands-Free Medical AI to 860,000 Clinicians." May 21, 2026. https://www.pymnts.com/healthcare/2026/openevidence-brings-hands-free-medical-ai-to-860000-clinicians/
2. Fierce Healthcare. "OpenEvidence clinches $250M Series D, rapidly growing its reach to doctors." January 2026. https://www.fiercehealthcare.com/ai-and-machine-learning/openevidence-clinches-250m-series-d-rapidly-growing-its-reach-doctors